Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias

Prognostic impact and targeting of CRM1 in acute myeloid leukemia

(2013) K. Kojima et al.   BLOOD

KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia

(2013) Julia Etchin et al.   BRITISH JOURNAL OF HAEMATOLOGY

Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas

(2013) A. S. Azmi et al.   HAEMATOLOGICA

How I treat CML blast crisis

(2012) R. Hehlmann   BLOOD

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

(2012) R. Lapalombella et al.   BLOOD

How I treat newly diagnosed chronic phase CML

(2012) J. Cortes et al.   BLOOD

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia

(2012) P. Ranganathan et al.   BLOOD

Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma

(2012) Kejie Zhang et al.   EXPERIMENTAL HEMATOLOGY

Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia

(2012) Maria Karvela et al.   Expert Review of Anticancer Therapy

Selective Inhibitors of Nuclear Export Block Pancreatic Cancer Cell Proliferation and Reduce Tumor Growth in Mice

(2012) Asfar S. Azmi et al.   GASTROENTEROLOGY

Consensus Induced Fit Docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitors

(2012) Ori Kalid et al.   JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN

Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells

(2012) J Etchin et al.   LEUKEMIA

Identification of CRM1-dependent Nuclear Export Cargos Using Quantitative Mass Spectrometry

(2012) Ketan Thakar et al.   MOLECULAR & CELLULAR PROTEOMICS

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

(2012) Jorge E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nuclear export of proteins and drug resistance in cancer

(2011) Joel G. Turner et al.   BIOCHEMICAL PHARMACOLOGY

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients

(2011) D. Milojkovic et al.   BLOOD

AU-rich RNA binding proteins in hematopoiesis and leukemogenesis

(2011) M. Baou et al.   BLOOD

Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression

(2011) C. M. Lucas et al.   BLOOD

Advances in the treatment of chronic myeloid leukemia

(2011) Anna M Eiring et al.   BMC Medicine

BCR–ABL1 kinase-dependent alteration of mRNA metabolism: potential alternatives for therapeutic intervention

(2011) Danilo Perrotti et al.   LEUKEMIA & LYMPHOMA

mRNA export and cancer

(2011) Nadeem Siddiqui et al.   Wiley Interdisciplinary Reviews-RNA

Philadelphia chromosome-positive acute lymphoblastic leukemia

(2010) Hun J. Lee et al.   CANCER

miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts

(2010) Anna M. Eiring et al.   CELL

Recognition of nuclear targeting signals by Karyopherin-β proteins

(2010) Darui Xu et al.   CURRENT OPINION IN STRUCTURAL BIOLOGY

Chronic myeloid leukemia: mechanisms of blastic transformation

(2010) Danilo Perrotti et al.   JOURNAL OF CLINICAL INVESTIGATION

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

Jak2 inhibition deactivates Lyn kinase through the SET–PP2A–SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients

(2009) A K Samanta et al.   ONCOGENE

Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer

(2008) Aurelia Noske et al.   CANCER

BCR/ABL Inhibits Mismatch Repair to Protect from Apoptosis and Induce Point Mutations

(2008) T. Stoklosa et al.   CANCER RESEARCH

Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation

(2008) R. K. Kancha et al.   HAEMATOLOGICA

The Karyopherin proteins, Crm1 and Karyopherin β1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation

(2008) Pauline J. van der Watt et al.   INTERNATIONAL JOURNAL OF CANCER

BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress

(2008) M Koptyra et al.   LEUKEMIA

Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis

(2007) A. M. Eiring et al.   BLOOD